Medtronic Resolute® Stent Shows Strong Performance in Heart Disease Patients With and Without Diabetes

According to study results presented at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, Medtronic’s Resolute® drug-eluting stent (DES) from Medtronic, Inc. yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.

New EU Min Three-Month Anti-Platelet Indication A First For Abbott’s XIENCE PRIME™ and XIENCE V® Drug Eluting Stents

Dual anti-platelet therapy is normally required for 6-12 months after implantation of a stent, with associated risks, costs and general inconvenience. No wonder then that Abbott is sounding pleased with itself as it gains the first indication of its kind to reduce the therapeutic period to a minimum of 3 months based on data from 10,000 patients.

CE Mark and EU Launch Of Boston Scientific’s Innova™ Self-expanding Bare-Metal Peripheral Vascular Stent

Boston Scientific Corporation has issued an announcement confirming CE Mark approval and European market launch of the Innova™ Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee.

Most read

Latest

^